Across TCGA pan-cancer cohorts, MRPS34 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MRPS34 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher MRPS34 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MRPS34 expression acts as an unfavorable survival marker.
LUSC are the cancer types where MRPS34 Mutation most reproducibly stratifies survival.